Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Capital Reinvestment Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Capital Reinvestment Ratio of 7.61x as of December 2023, meaning it reinvests 8% of its operating cash flow (CN¥90.45 Million) in capital expenditures (CN¥688.60 Million). See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Capital Reinvestment Ratio (2019–2023)
This chart tracks Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Capital Reinvestment Ratio across 5 annual periods. Check 301096 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2023)
Year-by-year Capital Reinvestment Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2023. For live market cap and broader valuation context, see 301096 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 7.61x | CN¥90.45 Million | CN¥688.60 Million | ▲ +233.8% |
| 2022 | 2.28x | CN¥259.41 Million | CN¥591.58 Million | ▲ +33.5% |
| 2021 | 1.71x | CN¥145.42 Million | CN¥248.45 Million | ▼ -63.6% |
| 2020 | 4.69x | CN¥54.36 Million | CN¥255.12 Million | ▲ +213.6% |
| 2019 | 1.50x | CN¥71.47 Million | CN¥106.95 Million | — |